tetano
Editor, Senior Moderator
J Neurol Sci
. 2020 Sep 19;418:117147.
doi: 10.1016/j.jns.2020.117147. Online ahead of print.
COVID-19 in multiple sclerosis patients and risk factors for severe infection
Farhan Chaudhry[SUP] 1 [/SUP], Helena Bulka[SUP] 2 [/SUP], Anirudha S Rathnam[SUP] 2 [/SUP], Omar M Said[SUP] 3 [/SUP], Jia Lin[SUP] 4 [/SUP], Holly Lorigan[SUP] 2 [/SUP], Eva Bernitsas[SUP] 4 [/SUP], Jacob Rube[SUP] 4 [/SUP], Steven J Korzeniewski[SUP] 3 [/SUP], Anza B Memon[SUP] 5 [/SUP], Phillip D Levy[SUP] 3 [/SUP], Lonni Schultz[SUP] 6 [/SUP], Adil Javed[SUP] 7 [/SUP], Robert Lisak[SUP] 4 [/SUP], Mirela Cerghet[SUP] 5 [/SUP]
Affiliations
Abstract
Multiple sclerosis (MS) patients have been considered a higher-risk population for COVID-19 due to the high prevalence of disability and disease-modifying therapy use; however, there is little data identifying clinical characteristics of MS associated with worse COVID-19 outcomes. Therefore, we conducted a multicenter prospective cohort study looking at the outcomes of 40 MS patients with confirmed COVID-19. Severity of COVID-19 infection was based on hospital course, where a mild course was defined as the patient not requiring hospital admission, moderate severity was defined as the patient requiring hospital admission to the general floor, and most severe was defined as requiring intensive care unit admission and/or death. 19/40(47.5%) had mild courses, 15/40(37.5%) had moderate courses, and 6/40(15%) had severe courses. Patients with moderate and severe courses were significantly older than those with a mild course (57[50-63] years old and 66[58.8-69.5] years old vs 48[40-51.5] years old, P = 0.0121, P = 0.0373). There was differing prevalence of progressive MS phenotype in those with more severe courses (severe:2/6[33.3%]primary-progressing and 0/6[0%]secondary-progressing, moderate:1/14[7.14%] and 5/14[35.7%] vs mild:0/19[0%] and 1/19[5.26%], P = 0.0075, 1 unknown). Significant disability was found in 1/19(5.26%) mild course-patients, but was in 9/15(60%, P = 0.00435) of moderate course-patients and 2/6(33.3%, P = 0.200) of severe course-patients. Disease-modifying therapy prevalence did not differ among courses (mild:17/19[89.5%], moderate:12/15[80%] and severe:3/6[50%], P = 0.123). MS patients with more severe COVID-19 courses tended to be older, were more likely to suffer from progressive phenotype, and had a higher degree of disability. However, disease-modifying therapy use was not different among courses.
Keywords: COVID-19; Coronavirus; Disease-modifying therapy; Multiple sclerosis; SARS-CoV-2019.
. 2020 Sep 19;418:117147.
doi: 10.1016/j.jns.2020.117147. Online ahead of print.
COVID-19 in multiple sclerosis patients and risk factors for severe infection
Farhan Chaudhry[SUP] 1 [/SUP], Helena Bulka[SUP] 2 [/SUP], Anirudha S Rathnam[SUP] 2 [/SUP], Omar M Said[SUP] 3 [/SUP], Jia Lin[SUP] 4 [/SUP], Holly Lorigan[SUP] 2 [/SUP], Eva Bernitsas[SUP] 4 [/SUP], Jacob Rube[SUP] 4 [/SUP], Steven J Korzeniewski[SUP] 3 [/SUP], Anza B Memon[SUP] 5 [/SUP], Phillip D Levy[SUP] 3 [/SUP], Lonni Schultz[SUP] 6 [/SUP], Adil Javed[SUP] 7 [/SUP], Robert Lisak[SUP] 4 [/SUP], Mirela Cerghet[SUP] 5 [/SUP]
Affiliations
- PMID: 32980780
- DOI: 10.1016/j.jns.2020.117147
Abstract
Multiple sclerosis (MS) patients have been considered a higher-risk population for COVID-19 due to the high prevalence of disability and disease-modifying therapy use; however, there is little data identifying clinical characteristics of MS associated with worse COVID-19 outcomes. Therefore, we conducted a multicenter prospective cohort study looking at the outcomes of 40 MS patients with confirmed COVID-19. Severity of COVID-19 infection was based on hospital course, where a mild course was defined as the patient not requiring hospital admission, moderate severity was defined as the patient requiring hospital admission to the general floor, and most severe was defined as requiring intensive care unit admission and/or death. 19/40(47.5%) had mild courses, 15/40(37.5%) had moderate courses, and 6/40(15%) had severe courses. Patients with moderate and severe courses were significantly older than those with a mild course (57[50-63] years old and 66[58.8-69.5] years old vs 48[40-51.5] years old, P = 0.0121, P = 0.0373). There was differing prevalence of progressive MS phenotype in those with more severe courses (severe:2/6[33.3%]primary-progressing and 0/6[0%]secondary-progressing, moderate:1/14[7.14%] and 5/14[35.7%] vs mild:0/19[0%] and 1/19[5.26%], P = 0.0075, 1 unknown). Significant disability was found in 1/19(5.26%) mild course-patients, but was in 9/15(60%, P = 0.00435) of moderate course-patients and 2/6(33.3%, P = 0.200) of severe course-patients. Disease-modifying therapy prevalence did not differ among courses (mild:17/19[89.5%], moderate:12/15[80%] and severe:3/6[50%], P = 0.123). MS patients with more severe COVID-19 courses tended to be older, were more likely to suffer from progressive phenotype, and had a higher degree of disability. However, disease-modifying therapy use was not different among courses.
Keywords: COVID-19; Coronavirus; Disease-modifying therapy; Multiple sclerosis; SARS-CoV-2019.